Search research articles
Contact Us
Filters
Showing results (51-60 of 77) with videos related to
Page
of 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2011
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project
Wendy B London, Victoria Castel, Tom Monclair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2009
Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience
Adela Canete, Mary Gerrard, Hervé Rubie, et al.
Cancer Research and Treatment
|
March 22, 2017
Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
Loredana Amoroso, Giovanni Erminio, Guy Makin, et al.
European Journal of Human Genetics : EJHG
|
April 23, 2022
Germline variant in Ctcf links mental retardation to Wilms tumor predisposition
Pablo Gargallo, Silvestre Oltra, María Tasso, et al.
Pediatric Blood & Cancer
|
April 26, 2017
Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes
Stefano Avanzini, Luca Pio, Giovanni Erminio, et al.
Journal of Neuroimmunology
|
July 12, 2016
Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma
Estefanía Torres-Vega, María Durán-Moreno, Manuel Sánchez Del Pino, et al.
Molecular Oncology
|
May 9, 2016
miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis
Pablo Berlanga, Lisandra Muñoz, Marta Piqueras, et al.
International Journal of Molecular Sciences
|
April 17, 2020
<i>MTHFR</i> and <i>VDR</i> Polymorphisms Improve the Prognostic Value of <i>MYCN</i> Status on Overall Survival in Neuroblastoma Patients
Gladys G Olivera, Yania Yáñez, Pablo Gargallo, et al.
Cancers
|
October 20, 2018
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
Nikolai Siebert, Sascha Troschke-Meurer, Madlen Marx, et al.
Breast Cancer Research and Treatment
|
February 14, 2009
CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers
Sarai Palanca Suela, Eva Esteban Cardeñosa, Eva Barragán González, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 77) with videos related to
Sort By:
Page
of 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2011
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project
Wendy B London, Victoria Castel, Tom Monclair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2009
Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience
Adela Canete, Mary Gerrard, Hervé Rubie, et al.
Cancer Research and Treatment
|
March 22, 2017
Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
Loredana Amoroso, Giovanni Erminio, Guy Makin, et al.
European Journal of Human Genetics : EJHG
|
April 23, 2022
Germline variant in Ctcf links mental retardation to Wilms tumor predisposition
Pablo Gargallo, Silvestre Oltra, María Tasso, et al.
Pediatric Blood & Cancer
|
April 26, 2017
Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes
Stefano Avanzini, Luca Pio, Giovanni Erminio, et al.
Journal of Neuroimmunology
|
July 12, 2016
Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma
Estefanía Torres-Vega, María Durán-Moreno, Manuel Sánchez Del Pino, et al.
Molecular Oncology
|
May 9, 2016
miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis
Pablo Berlanga, Lisandra Muñoz, Marta Piqueras, et al.
International Journal of Molecular Sciences
|
April 17, 2020
<i>MTHFR</i> and <i>VDR</i> Polymorphisms Improve the Prognostic Value of <i>MYCN</i> Status on Overall Survival in Neuroblastoma Patients
Gladys G Olivera, Yania Yáñez, Pablo Gargallo, et al.
Cancers
|
October 20, 2018
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
Nikolai Siebert, Sascha Troschke-Meurer, Madlen Marx, et al.
Breast Cancer Research and Treatment
|
February 14, 2009
CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers
Sarai Palanca Suela, Eva Esteban Cardeñosa, Eva Barragán González, et al.
Page
of 8